Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity
Viruses · 2026
DOI: 10.3390/v18090998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Sarah-Kim Friedrich-Becker und 11 weiteren Autor:innen. Beteiligte Einrichtung: Abalos Therapeutics GmbH, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Lymphocytic choriomeningitis virus, Mutation, Neoplasms, Viral Tropism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The development of effective viroimmunotherapies for cancer relies on the ability of replicating viruses to infect the entire tumor tissue and induce comprehensive inflammation within the tumor microenvironment (TME). In this study, we investigate the impact of mutations in the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV) on tumor cell infectivity, replication, and the immune response. Specifically, we focus on two key positions in GP1 (181 and 185) that significantly enhance tumor cell infectivity and improve CD8+ T cell function in the GP-mutated LCMV strain LCMV P52. Our findings demonstrate that LCMV strain LCMV P52 replicates preferentially in vivo in tumors, exhibits improved tumor penetration, attracts functional CD8+ T cells more effectively to the tumor, and reprograms the tumor toward a more immunogenic microenvironment to allow for effective checkpoint inhibitor combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Abalos Therapeutics GmbH, 40225 Düsseldorf, Germany.
- Institute of Immunology, University Hospital of Essen, 45147 Essen, Germany.
- National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, 01309 Dresden, Germany.
- Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany.
ORCID-Profile: Michael Bergerhausen, Rosa Schmitz, Lisa Holnsteiner
Zitieren
APA
Friedrich-Becker, S. K., Bergerhausen, M., Berry, A., Bhat, H., Li, F., Schmitz, R., Holnsteiner, L., Müller, D., Xu, H., Lang, P. A., Lang, K. S., & Vollmer, J. (2026). Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity. Viruses. https://doi.org/10.3390/v18090998
Vancouver
Friedrich-Becker SK, Bergerhausen M, Berry A, Bhat H, Li F, Schmitz R, et al. Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity. Viruses. 2026. doi:10.3390/v18090998
BibTeX
@article{FriedrichBecker2026,
author = {Friedrich-Becker, Sarah-Kim and Bergerhausen, Michael and Berry, Arshia and Bhat, Hilal and Li, Fanghui and Schmitz, Rosa and Holnsteiner, Lisa and Müller, Dethardt and Xu, Haifeng and Lang, Philipp A and Lang, Karl Sebastian and Vollmer, Jörg},
title = {Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18090998}
}
EUVIMED